HI
ITCI

HBK Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

HBK Investments’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,385,000
Closed -$578M – 257
2025
Q1 		$578M Buy
+4,385,000
New +$546M 8.17% 3
2019
Q1 		– Sell
-53,534
Closed -$610K – 1397
2018
Q4 		$610K Buy
53,534
+41,735
+354% +$674K 0.01% 842
2018
Q3 		$256K Sell
11,799
-49,901
-81% -$1.04M ﹤0.01% 1088
2018
Q2 		$1.09M Buy
+61,700
New +$1.25M 0.01% 621
2017
Q4 		– Sell
-300,000
Closed -$4.73M – 1165
2017
Q3 		$4.73M Buy
+300,000
New +$4.4M 0.03% 266
2015
Q4 		– Sell
-23,794
Closed -$953K – 1144
2015
Q3 		$953K Buy
+23,794
New +$776K 0.01% 602

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

HBK Investments's ITCI Position: Q2 2025 in Review

HBK Investments sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 4,385,000 shares — an estimated $578M sold.

HBK Investments first reported a position in ITCI in Q3 2015 and held it in 6 quarters. The position peaked at $578M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • HBK Investments reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • HBK Investments sold 4,385,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $578M.
  • HBK Investments first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 6 quarters.
  • HBK Investments's Intra-Cellular Therapies Inc. position peaked at $578M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on HBK Investments's 13F filing for Q2 2025, filed 13 Aug 2025.